Published in Contraception on March 01, 2010
Study of Pain Control With Hormonal IUS Insertion (SOPHI) | NCT02352714
Effect of Multimodal Analgesia on Pain With Insertion of Levonorgestrel-releasing IUD | NCT02799641
Pain Relief During IUD Insertion in Women Delivered Only by Elective Cesarean Section | NCT03587077
Practical advice for avoidance of pain associated with insertion of intrauterine contraceptives. J Fam Plann Reprod Health Care (2013) 3.72
Management of pain associated with the insertion of intrauterine contraceptives. Hum Reprod Update (2013) 0.96
Failed IUD insertions in community practice: an under-recognized problem? Contraception (2012) 0.84
The methodology for developing a prospective meta-analysis in the family planning community. Trials (2011) 0.79
Bleeding pattern and user satisfaction in second consecutive levonorgestrel-releasing intrauterine system users: results of a prospective 5-year study. Hum Reprod (2014) 0.78
Contraception for Adolescents: Focusing on Long-Acting Reversible Contraceptives (LARC) to Improve Reproductive Health Outcomes. Curr Obstet Gynecol Rep (2015) 0.75
Objective Assessment of Cervical Stiffness after Administration of Misoprostol for Intrauterine Contraceptive Insertion. Ultrasound Int Open (2016) 0.75
Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence (2013) 0.75
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Practical advice for avoidance of pain associated with insertion of intrauterine contraceptives. J Fam Plann Reprod Health Care (2013) 3.72
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Efficacy of contraceptive methods: A review of the literature. Eur J Contracept Reprod Health Care (2010) 2.92
Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet (2002) 2.86
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol (2013) 2.26
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. J Fam Plann Reprod Health Care (2013) 2.07
Embracing post-fertilisation methods of family planning: a call to action. J Fam Plann Reprod Health Care (2013) 2.04
Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy. Menopause (2005) 2.03
Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception (2006) 1.90
Seminal fluid induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus. J Immunol (2012) 1.65
Emergency contraception and fertility awareness among university students in Kampala, Uganda. Afr Health Sci (2006) 1.59
Quality of life and costs of levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of menorrhagia: a 10-year randomized controlled trial. Am J Obstet Gynecol (2013) 1.58
Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol (2005) 1.57
Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety. Int J Womens Health (2012) 1.52
The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower abdominal pain and back pain among women treated for menorrhagia: a five-year randomized controlled trial. Acta Obstet Gynecol Scand (2009) 1.43
The CHOICE study: effect of counselling on the selection of combined hormonal contraceptive methods in 11 countries. Eur J Contracept Reprod Health Care (2012) 1.19
Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture model. Hum Reprod (2007) 1.11
Pitfalls of research linking the intrauterine device to pelvic inflammatory disease. Obstet Gynecol (2013) 1.05
Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol (2009) 1.00
Tolerability and clinical safety of Implanon. Eur J Contracept Reprod Health Care (2008) 0.99
WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: Efficacy. BJOG (2003) 0.99
Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstet Gynecol (2013) 0.99
Effect of emergency contraception with levonorgestrel or mifepristone on ovarian function. Contraception (2004) 0.99
Effect of levonorgestrel and mifepristone on endometrial receptivity markers in a three-dimensional human endometrial cell culture model. Fertil Steril (2008) 0.98
The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review. Drugs (2012) 0.97
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer (2011) 0.95
Acceptability of home-use of misoprostol in medical abortion. Contraception (2004) 0.95
Toward an ecstasy and other club drug (EOCD) prevention intervention for rave attendees. J Drug Educ (2004) 0.95
Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol (2003) 0.95
3D Ultrastructural organization of whole Chlamydomonas reinhardtii cells studied by nanoscale soft x-ray tomography. PLoS One (2012) 0.95
Anal sphincter lacerations and upright delivery postures--a risk analysis from a randomized controlled trial. Int Urogynecol J Pelvic Floor Dysfunct (2006) 0.94
Use of contraceptive methods and contraceptive recommendations among health care providers actively involved in contraceptive counseling -- results of an international survey in 10 countries. Contraception (2012) 0.94
Regional differences in surgical intervention following medical termination of pregnancy provided by telemedicine. Acta Obstet Gynecol Scand (2011) 0.93
Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine system. Int J Gynaecol Obstet (2011) 0.93
A randomized trial among women with heavy menstruation -- impact of a decision aid on treatment outcomes and costs. Health Expect (2004) 0.93
WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. BJOG (2004) 0.91
Barriers and facilitators in the provision of post-abortion care at district level in central Uganda - a qualitative study focusing on task sharing between physicians and midwives. BMC Health Serv Res (2014) 0.91
Correlates of women's preferences for treatment of heavy menstrual bleeding. Patient Educ Couns (2003) 0.91
Effects of ovarian high response on implantation and pregnancy outcome during controlled ovarian hyperstimulation (with GnRH agonist and rFSH). Acta Obstet Gynecol Scand (2007) 0.90
Effects of ovarian stimulation on endometrial integrin beta3 and leukemia inhibitory factor expression in the peri-implantation phase. Fertil Steril (2007) 0.89
Simplified follow-up after medical abortion using a low-sensitivity urinary pregnancy test and a pictorial instruction sheet in Rajasthan, India--study protocol and intervention adaptation of a randomised control trial. BMC Womens Health (2014) 0.89
Fertility after discontinuation of contraception: a comprehensive review of the literature. Contraception (2011) 0.88
Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: one-year results of an observational study. Eur J Contracept Reprod Health Care (2011) 0.88
Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. Eur J Obstet Gynecol Reprod Biol (2005) 0.88
Downregulation of cilia-localized Il-6R alpha by 17beta-estradiol in mouse and human fallopian tubes. Am J Physiol Cell Physiol (2009) 0.87
Medical students' knowledge, attitudes and perceptions towards contraceptive use and counselling: a cross-sectional survey in Maharashtra, India. BMJ Open (2013) 0.87
The levonorgestrel intrauterine system: long-term contraception and therapeutic effects. Womens Health (Lond Engl) (2005) 0.87
Progesterone receptor isoform B in the human fallopian tube and endometrium following mifepristone. Contraception (2003) 0.86
Knowledge, attitudes and prescribing pattern of emergency contraceptives by health care workers in Kampala, Uganda. Acta Obstet Gynecol Scand (2007) 0.85
Endometrial receptivity and human embryo implantation. Am J Reprod Immunol (2011) 0.85
The influence of early cleavage on embryo developmental potential and IVF/ICSI outcome. J Assist Reprod Genet (2009) 0.85
Clomiphene citrate causes aberrant tubal apoptosis and estrogen receptor activation in rat fallopian tube: implications for tubal ectopic pregnancy. Biol Reprod (2009) 0.84
Impact of patient information booklet on treatment decision--a randomized trial among women with heavy menstruation. Health Expect (2003) 0.84
Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS). Acta Obstet Gynecol Scand (2011) 0.84
Assessment of significant factors affecting acceptability of home administration of misoprostol for medical abortion. Contraception (2011) 0.84
Teaching medical students gynaecological examination using professional patients-evaluation of students' skills and feelings. Med Teach (2005) 0.84
Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin Oncol (2009) 0.84
Levonorgestrel-releasing intrauterine system versus conventional medical therapy for heavy menstrual bleeding in the Asia-Pacific region. Int J Gynaecol Obstet (2013) 0.84
Cost-utility of levonorgestrel intrauterine system compared with hysterectomy and second generation endometrial ablative techniques in managing patients with menorrhagia in the UK. Curr Med Res Opin (2007) 0.83
Aquaporin 1 is expressed in the human endometrium during normal cycle and increases after mifepristone treatment. Int J Mol Med (2008) 0.82
Faced with a double-edged risk: Ugandan university students' perception of the emergency contraceptive pill in Uganda. Afr J Reprod Health (2009) 0.82
Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol (2014) 0.82
Factors predicting choice of treatment for menorrhagia in gynaecology outpatient clinics. Soc Sci Med (2003) 0.82
Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women. Contraception (2012) 0.82
Bleeding patterns with the levonorgestrel-releasing intrauterine system when used for heavy menstrual bleeding in women without structural pelvic pathology: a pooled analysis of randomized controlled studies. Contraception (2012) 0.82
Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20 μg/drospirenone 3mg administered in a 24/4 regimen: a pooled analysis of four open-label studies. Eur J Obstet Gynecol Reprod Biol (2011) 0.82
Molecular profiling of polycystic ovaries for markers of cell invasion and matrix turnover. Fertil Steril (2005) 0.82
Reason for the increasing use of vacuum extraction in Sweden: a population-based study. Acta Obstet Gynecol Scand (2013) 0.81
Recent advances in understanding endometrial receptivity: molecular basis and clinical applications. Am J Reprod Immunol (2014) 0.81
Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive. Contraception (2009) 0.81
Endometriosis and autoimmune disease: association of susceptibility to moderate/severe endometriosis with CCL21 and HLA-DRB1. Fertil Steril (2010) 0.81
Expressions of steroid receptors and Ki67 in first-trimester decidua and chorionic villi exposed to levonorgestrel used for emergency contraception. Fertil Steril (2008) 0.81
Expression of aquaporin 2 in human endometrium. Fertil Steril (2006) 0.80
Coadministration of estradiol/drospirenone and indomethacin does not cause hyperkalemia in healthy postmenopausal women: a randomized open-label crossover study. J Clin Pharmacol (2007) 0.80
Factors influencing women's selection of combined hormonal contraceptive methods after counselling in 11 countries: results from a subanalysis of the CHOICE study. Eur J Contracept Reprod Health Care (2013) 0.79
The effect of orally and vaginally administered misoprostol on inflammatory mediators and cervical ripening during early pregnancy. Contraception (2005) 0.79
Emergency contraception. Best Pract Res Clin Endocrinol Metab (2012) 0.79
Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol (2011) 0.79
Depressive symptoms as predictors of discontinuation of treatment of menorrhagia by levonorgestrel-releasing intrauterine system. Int J Behav Med (2007) 0.79
Early versus delayed insertion of intrauterine contraception after medical abortion - a randomized controlled trial. PLoS One (2012) 0.79
Effects of mifepristone on expression of endothelial nitric oxide synthase in human endometrium during the implantation phase. Fertil Steril (2003) 0.79
Intrauterine nitric oxide in pelvic inflammatory disease. Fertil Steril (2007) 0.79
Expression of heparin-binding epidermal growth factor-like growth factor and its receptors in the human fallopian tube and endometrium after treatment with mifepristone. Fertil Steril (2006) 0.78
An historical overview of second trimester abortion methods. Reprod Health Matters (2008) 0.78
A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen. Eur J Obstet Gynecol Reprod Biol (2012) 0.78
CD44v6 in developing, dysplastic and malignant oral epithelia. Oral Oncol (2003) 0.78
The effect of mifepristone on the expression of insulin-like growth factor binding protein-1, prolactin and progesterone receptor mRNA and protein during the implantation phase in human endometrium. Mol Hum Reprod (2002) 0.77
Perceptions of contraception, non-protection and induced abortion among a sample of urban Swedish teenage girls: focus group discussions. Eur J Contracept Reprod Health Care (2006) 0.77
Polyethylene glycated leukemia inhibitory factor antagonist inhibits human blastocyst implantation and triggers apoptosis by down-regulating embryonic AKT. Fertil Steril (2013) 0.77
Clinician satisfaction and insertion characteristics of a new applicator to insert radiopaque Implanon: an open-label, noncontrolled, multicenter trial. Contraception (2010) 0.77
GSTM1 gene expression correlates to leiomyoma volume regression in response to mifepristone treatment. PLoS One (2013) 0.77